Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

72.33 0.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

72.25

Max

72.34

Belangrijke statistieken

By Trading Economics

Inkomsten

3.6M

55M

Verkoop

9.8M

321M

K/W

Sectorgemiddelde

62.405

57.371

EPS

0.49

Dividendrendement

0.44

Winstmarge

17.006

Werknemers

3,000

EBITDA

-6.7M

92M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.24% downside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

0.44%

2.23%

Volgende Winsten

4 nov 2026

Volgende dividenddatum

28 aug 2026

Volgende Ex Dividend datum

24 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

42M

11B

Vorige openingsprijs

72.3

Vorige sluitingsprijs

72.33

Nieuwssentiment

By Acuity

50%

50%

171 / 340 Rangschikking in Healthcare

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 aug 2026, 19:27 UTC

Correlated Moves

Shares modestly higher, influenced by rise in iShares Biotechnology ETF.

18 aug 2026, 21:41 UTC

Bio-Techne Corp shares are higher in after-market trading, peaking early in the session and remaining near the upper end of their one-month trading range.

17 aug 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat amid broader market sentiment, with the Russell 2000 Index declining. Recent economic data has contributed to cautious conditions.

13 aug 2026, 19:16 UTC

Correlated Moves
News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5 aug 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4 aug 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3 aug 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31 jul 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30 jul 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29 jul 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20 jul 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

-0.24% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 72.11 USD  -0.24%

Hoogste 73 USD

Laagste 65 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

11 ratings

0

Buy

11

Hold

0

Sell

Sentiment

By Acuity

171 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat